LAUNCH
Sexual and Reproductive Health Research & Development: Beyond Spillovers

11 October 2023
G-FINDER Thematic areas

- Poverty-Related Neglected Diseases
- Emerging Infectious Diseases
- Sexual and Reproductive Health
Beyond spillovers

- Sexually transmitted infections (STIs)
- HPV and HPV-related cervical cancer
- Contraception
- Multipurpose prevention technologies (MPTs)
- Pre-eclampsia and eclampsia
- Post-partum haemorrhage (PPH)
- R&D for more than one issue
SRH R&D funding 2018-2021
SRH R&D funding grew by $200m, but funding is not equal...
Most of growth came from increases in sexually transmitted infection R&D funding...

Sexually transmitted infection R&D funding by product type (2018 – 2021)

SEXUALLY TRANSMITTED INFECTIONS

- Total R&D spend 2021
- Cumulative R&D spend 2018-2021
- Total R&D spend 2018-2021
- % change from 2020
- Sector share
- R&D stage share

$146m
$488m
-8.9%

LMIC APPLICABLE R&D FUNDING IN 2021

Public
Philanthropic
Private

Basic & early
Late
Unspecified

Unspecified
Diagnostics
Microbicides
Biologics
Vaccines
Drugs
Basic research
...as well as increases in related issues such as HPV and HPV-related cervical cancer.

HPV & HPV-related cervical cancer R&D funding by product type (2018 – 2021)
Contraceptive R&D funding has largely stagnated, and started to fall
MPT R&D funding has rebounded from a two year dip
But funding for maternal health issues is lagging behind
Preeclampsia & eclampsia R&D funding is steadily falling

Preeclampsia R&D funding by product type (2018 – 2021)
..as is funding for postpartum haemorrhage R&D

Postpartum haemorrhage R&D funding by product type (2018 – 2021)
Although the pipeline looks reasonable but isn’t the full story...

PPH pipeline products includes candidates investigated to treat PPH from 2000-2023. Pipeline products for all other maternal health conditions includes candidates investigated between 2000-2021.
Looking past the numbers
Increasing share of burden in HICs is a reasonably accurate predictor of how much money was spent on it.
SRH R&D has benefited from COVID-driven increased investments for platform technologies.
Some SRH R&D funding is becoming more diverse.
Funding for SRH R&D has become more diverse…and there is optimism that this will continue & grow.
Overall though, R&D funding to SRH pales in comparison to other global health areas.
Q&A
Looking to the future of the G-FINDER SRH report
What criteria do we need to answer this question specifically with an LMIC lens?

**Within a global health context**, what is being spent and done in biomedical innovation for women’s health?
Women’s Health R&D: a feminist lens on global health R&D

Global health R&D ecosystem
- e.g., inclusion/representation in CTs, preclinical/discovery, R&D leadership roles, R&D priority setting, pipeline

Neglected diseases
- e.g., HIV, malaria, schistosomiasis

Emerging Infectious diseases
- e.g., COVID, Zika

Sexual & reproductive health
- e.g., STIs, HPV, contraception, MPTs, pregnancy-related conditions, gynaecological health issues, menstrual and menopause health

Chronic & non-communicable diseases
- e.g., cancers, heart disease, Alzheimer’s
“Women’s health” is often defined in the context of conditions exclusive to women.
But what about things that affect women disproportionately & differently?
But really we only have a fraction of the data...so far
Women's Health R&D: A feminist lens on global health R&D

**Global health R&D ecosystem**
- e.g., inclusion/representation in CTs, preclinical/discovery, R&D leadership roles, R&D priority setting, pipeline

**Neglected diseases**
- e.g., HIV, malaria, schistosomiasis

**Emerging Infectious diseases**
- e.g., COVID, Zika

**Sexual & reproductive Health +**
- e.g., STIs, HPV, contraception, MPTs, pregnancy-related conditions, gynaecological health issues, menstrual and menopause health

**Chronic & non-communicable diseases**
- e.g., cancers, heart disease, Alzheimer's
Thank you!